GSA CAPITAL PARTNERS LLP

Position in ZNTL — Zentalis Pharmaceuticals, Inc.

CIK 1362033 LONDON, X0

Position in ZNTL

as of Mar 31, 2026 · filed May 8, 2026 Compact

Position Value

$1,451,752

-$127,171 QoQ

Shares Held

620,407

-47.0% QoQ

Ownership

0.872%

of shares outstanding

% of Portfolio

0.10%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2021

12 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

GSA CAPITAL PARTNERS LLP holds $101,563,069 across 163 Biotechnology names. ZNTL ranks #17 (1.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	REGN	Regeneron Pharmaceuticals, Inc.	3,831	$2,959,983
2	ARDX	Ardelyx, Inc.	473,061	$2,833,635
3	NTLA	Intellia Therapeutics, Inc.	178,301	$2,285,818
4	NUVB	Nuvation Bio Inc.	495,792	$2,126,947
5	RXRX	Recursion Pharmaceuticals, Inc.	669,568	$2,055,573
6	WVE	Wave Life Sciences Ltd.	282,719	$2,049,712
7	SRPT	Sarepta Therapeutics, Inc.	90,960	$1,979,289
8	IOVA	Iovance Biotherapeutics, Inc.	557,085	$1,955,368

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,451,752	620,407	-47.0%	Shares	Sole	2026-05-08
2025-12-31	$1,578,923	1,169,573	+8.5%	Shares	Sole	2026-02-06
2025-09-30	$1,627,260	1,077,656	-4.9%	Shares	Sole	2025-11-07
2025-06-30	$1,314,715	1,133,375	+109.1%	Shares	Sole	2025-07-22
2025-03-31	$861,740	541,975	+275.9%	Shares	Sole	2025-05-08
2024-12-31	$436,835	144,170	-76.3%	Shares	Sole	2025-02-07
2024-09-30	$2,239,592	608,585	+138.5%	Shares	Sole	2024-11-05
2024-06-30	$1,043,772	255,201	+2307.1%	Shares	Sole	2024-08-15
2024-03-31	$167,087	10,602	-56.4%	Shares	Sole	2024-05-03
2023-09-30	$488,340	24,344	+87.6%	Shares	Sole	2023-11-15
2022-03-31	$598,851	12,979	-51.7%	Shares	Sole	2022-05-11
2021-12-31	$2,258,187	26,864	—	Shares	Sole	2022-02-14
No filing history on record for this holder in this stock.